TheraRadar
Clinical-Stage Companies / American Regent

American Regent

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 2/1/2025

25
Total Trials
12
Phase 3
6
Phase 2
0
Recruiting
237
Score

Pipeline by Phase

Phase 3
12
Phase 2
6
Phase 1
3

Therapeutic Focus

Iron Deficiency Anemia Anemia Iron Deficiency Anemia (IDA) Restless Legs Syndrome (RLS) Myelodysplastic Syndrome

Clinical Trials (25)

NCT02527213 Phase 3 WITHDRAWN

Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy

Started: 1/30/2015

NCT03037931 Phase 3 COMPLETED

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Started: 3/15/2017

NCT03523117 Phase 3 COMPLETED

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Started: 1/31/2019

NCT04269707 Phase 3 COMPLETED

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Started: 11/19/2019

NCT02397057 Phase 3 COMPLETED

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

Started: 1/1/2015

NCT02453334 Phase 3 COMPLETED

Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®

Started: 5/23/2015

NCT00981045 Phase 3 COMPLETED

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

Started: 8/1/2009

NCT00703937 Phase 3 COMPLETED

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia

Started: 7/1/2008

NCT00704353 Phase 3 COMPLETED

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

Started: 6/1/2008

NCT00704028 Phase 3 COMPLETED

Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia

Started: 6/1/2008

NCT00982007 Phase 3 COMPLETED

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Started: 9/1/2009

NCT01819610 Phase 3 COMPLETED

Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures

Started: 2/1/2013

NCT02826681 Phase 2 TERMINATED

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

Started: 7/10/2017

NCT04968379 Phase 2 WITHDRAWN

Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

Started: 7/21/2022

NCT02410213 Phase 2 COMPLETED

A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA

Started: 2/19/2015

NCT02409459 Phase 2 COMPLETED

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Started: 3/1/2015

NCT01307007 Phase 2 COMPLETED

Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding

Started: 9/1/2010

NCT01290315 Phase 2 COMPLETED

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Started: 8/1/2009

NCT01290302 Phase 1 COMPLETED

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Started: 11/22/2010

NCT02478281 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

Started: 10/1/2012

NCT01365624 Phase 1 COMPLETED

Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects

Started: 2/1/2008

NCT01950247 Phase 4 COMPLETED

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

Started: 8/15/2013

NCT05661682 Phase 4 WITHDRAWN

Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety

Started: 2/1/2025

NCT05677126 Phase 4 WITHDRAWN

Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN

Started: 8/1/2024

NCT02086968 Phase 4 COMPLETED

Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

Started: 1/1/2014

Drug Candidates

Luitpold Azacitidine Vidaza® Methylene Blue Injectafer SOC Sodium thiosulfate Placebo Injectafer® (Ferric Carboxymaltose - FCM) Placebo (Normal Saline) Tralement
Activity Status: Slowing
Last Trial Started: 2/1/2025
Last Trial Ended: 2/2/2023
Trials (12 months): 0
Completed Trials: 20
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.